Member Info for ForFXSake

Not too long to wait then, although if it goes to the wire then I can't imagine that they will not have too much of interest to report.

My wish would be to get a massive licensing deal AND achieve world peace AND to finally get to see Santa climbing down the chimney to deliver my socks on Xmas eve.

Is that asking a bit much?

Fair enough, I'll settle for World peace and Santa but I'll just keep my fingers crossed for a new CEO.

Could this provide increased market access to companies
like Ebers (if they can bothered, that is)?

BBC News - US House passes federal cannabis decriminalisation bill
https://www.bbc.co.uk/news/world-us-canada-55191808

It is interesting how both NED's have been appointed to Nomination & Audit Committee (from Vox news article). I wasn't sure what the purpose of the Committee was but found this:

"These committees are tasked with a series of responsibilities. One of their primary duties is to seek out candidates to fill a variety of important positions in a company including its board of directors as well as key management roles. The committees review candidates' qualifications and ensure they align with the requirements of the company. More about this is outlined a little further down."

Alongside the fact that JG has previously raised private and public funds to the tune of £100m, it strengthens my fears that they may be planning an internal recruitment drive for in-house development.

Indifferent. Hiring new blood is one thing, closing deals is another.

I'm still concerned that they will try progress things in-house without a partner. That will be expensive and require major funding....which means major dilution for us.

We need a deal.

I agree that the CEO may already have been found and may be working their notice. Time will tell.

NED appointments seem to be loosely coupled to organisations these days. They don't seem to operate in the same way as permanent staff. They may have positions with other companies and may be remunerated in ways that don't involve salary. I don't think short term, incentivised appointments of NED's with specific skills to get a deal across the line would unreasonable. A CEO, on the other hand, is a full time role.

Perhaps not but they did reiterate the search for another NED when the RNS for JG was released, why not CEO & NED?

It could be nothing, just thought I'd point it out as I thought it was odd.

Sorry, Waccamacca

Dunno Waccamamma.

I said a faint whiff, simply because they've gone from saying they need a CEO to move forward, to now not mentioning it at all. Why would you no longer need a CEO?

"Over recent months, the Board has undertaken a substantial amount of work to position the business for growth. The focus continues to be driving maximum value for shareholders with a number of key opportunities. In order to execute these, the Group requires additional expertise and an appropriate infrastructure, with a heightened focus on business development. Following the business review, the Group needs to bring in a CEO and augment the Board with additional Non-Executive expertise."

I am intrigued by why they appear to have dropped the requirement for a CEO? Do they no longer need one to move forward? Why no announcement that CB will continue in the role on a permanent basis.

We have 2 NED's appointed immediately and in quick succession. One who appears to be well grounded in growing products to either be sold on or brought to market, who also has previous with CINV. Another with a strong financial background who will be immediately "useful for near term objectives".

Anyone else get a faint whiff of possible M&A brewing?

I seem to remember someone recently saying not to worry as we never stay below 3p for long...now that was tempting fate. I've forgotten what the heady days of 4p felt like.

Personal circumstances are usually the drivers for commercial success. If a board doesn't get on, it can have devastating consequences.

Don't forget, he left Acacia in 2019, so I doubt discussions were required for his appointment to NFX

I agree, any deal would be better than no deal.

Although it would be great if a big pharma company like Sosei was in the sidelines, I don't see it at present. I do think that CINV is the reason for JG's appointment but Acacia already have APD403 as a CINV solution. Unless it is far less promising or further from market than NXP001, then I can't see why they would be interested in acquiring another.

It is interesting that JG appears to still hold a 2% stake in Acacia though. He may still be influential. I suppose that all depends on whether or not his exit from Acacia was driven by internal wranglings or his own desire to step aside.

I have seen that Mars.

What I'm saying is that Sosei bought Arakis out for their COPD drug and I can't see anything to suggest that they also have an interest in Acacia or PONV/CINV, they don't seem to specialise in it.

There does seem to be a relevant developing link between Acacia, Gilbert, CINV and NXP001...but I can't see any evidence of big pharma being involved.

Maybe a deal could be on the cards with Acacia at some point but with a valuation of 218m, I'm not sure how great that deal would be for us compared to one done with big pharma.

I may have missed something here guys but why is Sosei being banded about as relevant?

As far as I understand, JG has founded 2 companies, Arakis which developed a COPD drug (and was bought out by Sosei for that drug) and Acacia, which appears appears to have a focus on nausea and vomiting but is independent and has just brought a drug to the US market.

Is Sosei somehow involved with Acacia as well? Do Sosei even have an interest in PONV/CINV?

Mr Gilbert's old company, Acacia seem to specialise in both Post Operative Nausea & Vomiting (Barhemsys) and CINV (APD403). I think it is therefore safe to say that Julian's appointment as NED is probably linked to the development of NXP001 in some way.

What is interesting is that a Julian Clive Gilbert still appears to hold 2.18% of Acacia (1.9m shares). Why might he be interested in the development of a competitors product to the extent that he would actually join as NED?

As a major shareholder, does Julian still have strong ties to the Acacia board? Barhemsys was successfully launched in the US market to treat PONV in August this year. Could Acacia now be looking to strengthen their CINV portfolio too?

Wake me up when something happens

Just took a peek at the 3 year chart.

It's a beautiful downtrend from the highs of 15p in May 19, I can almost connect all the peaks into a straight line!

The great news is that we are about to hit a major support level at 2p, it looks very strong. That should hopefully hold for a little while.

The RNS did not mention the search for a CEO, just another NED.

Either they've already found one and are waiting to announce or they've given up (which would be odd considering they said they needed one to move things forward).